Metabromsalan

Summary

Metabromsalan (CHEMBL1801800) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 371.02 Da · C13H9Br2NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1801800
Name	Metabromsalan
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	17404
Molecular formula	C13H9Br2NO2
Molecular weight	371.02
InChIKey	YALKQBRWLMDVSA-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)NC(=O)C2=C(C(=CC(=C2)Br)Br)O

IUPAC name: 3,5-dibromo-2-hydroxy-N-phenylbenzamide

Also known as: Metabromsalan, NSC-526280, METABROMSALAN

Patent coverage: 3,238 distinct patent families (6,102 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,809 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: HSP60/HSP10.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).